i3 Research Acquires SKM Oncology

BASKING RIDGE, NJ, June 20, 2005 - i3 Research, a global contract research organization (CRO) providing clinical trial services specialized in oncology, central nervous system, respiratory and infectious disease, has acquired SKM Oncology and its related businesses. SKM is a full-service CRO and a leader in the delivery of oncology clinical trials in Germany. Its coverage and strength in the key German marketplace, coupled with i3's therapeutic specialization and geographic reach, elevate i3 to a global leadership position in the oncology product development marketplace.

"The SKM acquisition fits perfectly into our specialization strategy to focus on a limited number of key therapeutic areas in which we know we can provide unparalleled quality clinical research services, rather than trying to become experts in every area," said Nigel Page, i3 Research president. "In addition to supplementing our capabilities in the oncology area, SKM provides us with a solid delivery platform for our services in the German market, and to Europe beyond."

Founded in 1996, SKM has four offices in Germany and one in Vienna, Austria. "The combined i3-SKM organization will provide our customers with exceptional access to oncology thought leaders and patients, and great experience in oncology trial delivery," said Renate Walter-Kirst, SKM founder and CEO. "It illustrates the investment and commitment i3 is making to bring ever-greater expertise, capabilities and value to its customers."